MA33849B1 - Formes cristallines de la 3-(2,6-dichloro-3,5-diméthoxy-phényl)-1- {6-[4-(4-éthyl-pipérazin-1-yl) -phénylamino] -pyrimidin-4-yl} -1-méthyl-urée et de ses sels - Google Patents

Formes cristallines de la 3-(2,6-dichloro-3,5-diméthoxy-phényl)-1- {6-[4-(4-éthyl-pipérazin-1-yl) -phénylamino] -pyrimidin-4-yl} -1-méthyl-urée et de ses sels

Info

Publication number
MA33849B1
MA33849B1 MA35005A MA35005A MA33849B1 MA 33849 B1 MA33849 B1 MA 33849B1 MA 35005 A MA35005 A MA 35005A MA 35005 A MA35005 A MA 35005A MA 33849 B1 MA33849 B1 MA 33849B1
Authority
MA
Morocco
Prior art keywords
piperazin
phenylamino
pyrimidin
dimethoxy
dichloro
Prior art date
Application number
MA35005A
Other languages
Arabic (ar)
English (en)
Inventor
Joerg Berghausen
Prasad Koteswara Kapa
Joseph Mckenna
Joel Slade
Raeann Wu
Zhengming Du
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43983750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33849(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33849B1 publication Critical patent/MA33849B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente technologie concerne de nouvelles formes cristallines anhydres et hydratées de 3-(2,6-dichloro-3,5-diméthoxy-phényl)-1-{6-[4-(4-éthyl-pipérazin-1-yl)-phénylamino]-pyrimidin-4-yl}-1-méthyl-urée, des polymorphes amorphes et cristallines anhydres de son sel d'acide monophosphorique, et le sel chlorhydrate, incluant son dihydrate. La présente technologie concerne également des procédés de préparation de diverses formes, des compositions les contenant et des procédés de traitement les employant.
MA35005A 2009-12-07 2012-06-26 Formes cristallines de la 3-(2,6-dichloro-3,5-diméthoxy-phényl)-1- {6-[4-(4-éthyl-pipérazin-1-yl) -phénylamino] -pyrimidin-4-yl} -1-méthyl-urée et de ses sels MA33849B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26715509P 2009-12-07 2009-12-07
PCT/US2010/059108 WO2011071821A1 (fr) 2009-12-07 2010-12-06 Formes cristallines de la 3-(2,6-dichloro-3,5-diméthoxy-phényl)-1-{6-[4-(4-éthyl-pipérazin-1-yl)-phénylamino]-pyrimidin-4-yl}-1-méthyl-urée et de ses sels

Publications (1)

Publication Number Publication Date
MA33849B1 true MA33849B1 (fr) 2012-12-03

Family

ID=43983750

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35005A MA33849B1 (fr) 2009-12-07 2012-06-26 Formes cristallines de la 3-(2,6-dichloro-3,5-diméthoxy-phényl)-1- {6-[4-(4-éthyl-pipérazin-1-yl) -phénylamino] -pyrimidin-4-yl} -1-méthyl-urée et de ses sels

Country Status (33)

Country Link
US (1) US9067896B2 (fr)
EP (1) EP2509963B1 (fr)
JP (2) JP5714024B2 (fr)
KR (1) KR101787784B1 (fr)
CN (5) CN111100078A (fr)
AR (2) AR079257A1 (fr)
AU (1) AU2010328391B2 (fr)
BR (1) BR112012013784B1 (fr)
CA (1) CA2781431C (fr)
CL (1) CL2012001480A1 (fr)
DK (1) DK2509963T3 (fr)
EC (1) ECSP12012026A (fr)
ES (1) ES2562462T3 (fr)
GT (1) GT201200181A (fr)
HK (1) HK1171016A1 (fr)
HR (1) HRP20160126T1 (fr)
HU (1) HUE026983T2 (fr)
IL (1) IL220012B (fr)
JO (1) JO3061B1 (fr)
MA (1) MA33849B1 (fr)
MX (1) MX2012006562A (fr)
MY (1) MY158333A (fr)
NZ (3) NZ600070A (fr)
PE (1) PE20121499A1 (fr)
PH (1) PH12014502593A1 (fr)
PL (1) PL2509963T3 (fr)
RU (1) RU2572848C2 (fr)
SG (1) SG10201408063SA (fr)
SI (1) SI2509963T1 (fr)
TN (1) TN2012000263A1 (fr)
TW (1) TWI526440B (fr)
WO (1) WO2011071821A1 (fr)
ZA (1) ZA201203612B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
RU2643326C2 (ru) * 2012-03-30 2018-01-31 Новартис Аг Ингибитор рецептора фрф для применения в лечении гипофосфатемических заболеваний
WO2014007951A2 (fr) 2012-06-13 2014-01-09 Incyte Corporation Composés tricycliques substitués utilisés comme inhibiteurs de fgfr
WO2014026125A1 (fr) 2012-08-10 2014-02-13 Incyte Corporation Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
EP2968337B1 (fr) 2013-03-15 2021-07-21 Celgene CAR LLC Composés hétéroaryle et utilisations associées
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
KR102350704B1 (ko) 2013-03-15 2022-01-13 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
WO2014155268A2 (fr) 2013-03-25 2014-10-02 Novartis Ag Inhibiteurs de kinase tyrosine fgf-r et leur utilisation dans le traitement de maladies associées à un manque ou à une absence d'activité snf5
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
CA2917667A1 (fr) * 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase pour le traitement d'une maladie
RS57444B1 (sr) * 2013-10-18 2018-09-28 Eisai R&D Man Co Ltd Pirimidin fgfr4 inhibitori
SI3079667T1 (sl) 2013-12-13 2019-10-30 Novartis Ag Farmacevtske dozirne oblike
WO2016027781A1 (fr) 2014-08-18 2016-02-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 Sel de dérivé de pyridine monocyclique et son cristal
US20170304313A1 (en) 2014-10-06 2017-10-26 Novartis Ag Therapeutic Combination For The Treatment Of Cancer
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
NZ773116A (en) 2015-02-20 2024-05-31 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
JP2018509448A (ja) * 2015-03-25 2018-04-05 ノバルティス アーゲー 組合せ医薬
EP3283465B1 (fr) 2015-04-14 2021-01-06 Eisai R&D Management Co., Ltd. Composé inhibiteur de fgfr4 cristallin et utilisations de celui-ci
CN104803925B (zh) * 2015-04-16 2018-01-12 温州医科大学 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途
WO2016189472A1 (fr) 2015-05-28 2016-12-01 Novartis Ag Inhibiteur de fgfr destiné à être utilisé dans le traitement de la tumeur mésenchymateuse phosphaturique
WO2017196854A1 (fr) 2016-05-10 2017-11-16 Eisai R&D Management Co., Ltd. Associations médicamenteuses permettant de réduire la viabilité et/ou la prolifération cellulaire
EP3459952B1 (fr) * 2016-05-20 2022-01-05 Zhejiang Hisun Pharmaceutical Co., Ltd. Dérivé pyrimidine, procédé de préparation et utilisation associée en médecine
CN109803684B (zh) * 2016-08-23 2022-08-23 卫材 R&D 管理有限公司 用于治疗肝细胞癌的组合疗法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107176954B (zh) 2017-06-02 2019-01-11 无锡双良生物科技有限公司 一种egfr抑制剂的药用盐及其晶型、制备方法和应用
US11440903B2 (en) 2017-11-01 2022-09-13 Guangdong Zhongsheng Pharmaceutical Co., Ltd Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof
CA3091153A1 (fr) 2018-03-28 2019-10-03 Eisai R&D Management Co., Ltd. Agent therapeutique pour le carcinome hepatocellulaire
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021067374A1 (fr) 2019-10-01 2021-04-08 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
BR112022007163A2 (pt) 2019-10-14 2022-08-23 Incyte Corp Heterociclos bicíclicos como inibidores de fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022221170A1 (fr) 2021-04-12 2022-10-20 Incyte Corporation Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
EP4352059A1 (fr) 2021-06-09 2024-04-17 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2022271933A1 (fr) 2021-06-23 2022-12-29 Kimtron, Inc. Système et procédé d'irradiation à proximité ultra-étroite d'une biomasse rotative
CN116768856A (zh) * 2022-03-18 2023-09-19 上海润石医药科技有限公司 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用
CN115785001B (zh) * 2022-11-23 2023-09-15 斯坦德药典标准物质研发(湖北)有限公司 一种英菲格拉替尼的制备方法
WO2024186882A1 (fr) 2023-03-06 2024-09-12 Qed Therapeutics, Inc. Méthodes de traitement de dysplasies squelettiques

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CN101242843A (zh) * 2005-06-10 2008-08-13 詹森药业有限公司 作为激酶调节剂的氨基嘧啶类化合物
KR101486490B1 (ko) * 2005-11-08 2015-01-27 제이더블유중외제약 주식회사 α-헬릭스 유사체 및 암 줄기세포의 치료에 관한 방법
ME00011A (fr) * 2005-12-21 2009-02-10 Novartis Ag Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fgf)
CN102016592A (zh) * 2008-04-29 2011-04-13 诺瓦提斯公司 监测成纤维细胞生长因子受体的激酶活性的调节的方法及所述方法的应用
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas

Also Published As

Publication number Publication date
TWI526440B (zh) 2016-03-21
NZ600070A (en) 2014-06-27
JP2015107996A (ja) 2015-06-11
EP2509963B1 (fr) 2015-11-25
ZA201203612B (en) 2013-01-30
AU2010328391A1 (en) 2012-06-07
CN111100078A (zh) 2020-05-05
SG10201408063SA (en) 2015-01-29
EP2509963A1 (fr) 2012-10-17
JP5714024B2 (ja) 2015-05-07
AR114946A2 (es) 2020-11-11
JP6019142B2 (ja) 2016-11-02
IL220012A0 (en) 2012-07-31
KR20130028045A (ko) 2013-03-18
ES2562462T3 (es) 2016-03-04
JO3061B1 (ar) 2017-03-15
IL220012B (en) 2018-02-28
JP2013512956A (ja) 2013-04-18
MY158333A (en) 2016-09-30
KR101787784B1 (ko) 2017-10-18
DK2509963T3 (en) 2016-02-29
AU2010328391B2 (en) 2014-07-03
CN105061332A (zh) 2015-11-18
PL2509963T3 (pl) 2016-05-31
RU2012128351A (ru) 2014-01-20
HRP20160126T1 (hr) 2016-03-25
GT201200181A (es) 2013-12-03
PH12014502593A1 (en) 2015-09-21
CN102639510A (zh) 2012-08-15
CA2781431A1 (fr) 2011-06-16
RU2572848C2 (ru) 2016-01-20
NZ624315A (en) 2014-11-28
NZ700778A (en) 2015-04-24
HUE026983T2 (en) 2016-08-29
ECSP12012026A (es) 2012-08-31
US20120245182A1 (en) 2012-09-27
MX2012006562A (es) 2012-07-04
BR112012013784A2 (pt) 2016-05-03
CN111269186A (zh) 2020-06-12
BR112012013784B1 (pt) 2021-11-03
CN111100077A (zh) 2020-05-05
US9067896B2 (en) 2015-06-30
TW201144297A (en) 2011-12-16
AR079257A1 (es) 2012-01-04
CA2781431C (fr) 2017-10-31
WO2011071821A1 (fr) 2011-06-16
HK1171016A1 (zh) 2013-03-15
PE20121499A1 (es) 2012-11-15
SI2509963T1 (sl) 2016-05-31
CL2012001480A1 (es) 2014-09-05
TN2012000263A1 (en) 2013-12-12
BR112012013784A8 (pt) 2017-12-26

Similar Documents

Publication Publication Date Title
MA33849B1 (fr) Formes cristallines de la 3-(2,6-dichloro-3,5-diméthoxy-phényl)-1- {6-[4-(4-éthyl-pipérazin-1-yl) -phénylamino] -pyrimidin-4-yl} -1-méthyl-urée et de ses sels
DE112009004421T8 (de) RFID-Abtastsystem ohne äußere Energieversorgung zur Abfrage des strukturellen Befindens
BRPI0911773A2 (pt) eletrodo frontal transparente para uso em dispositivo fotovoltaico e método de produção do mesmo
BRPI0907004A2 (pt) Eletrodo frontal para uso em dispositivo fotovoltaico e método de produção do mesmo
BRPI0922095A2 (pt) derivados de piridina e pirimidina como inibidores de fosfodiesterase 10
MX2010007784A (es) 2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran -4-il)-propionamida cristalina.
BRPI0922489A2 (pt) amida de ácido 4-(1,2,3,4-tetrahidroisoquinolina-2-il)-4-oxobutírico como modulares de kcnq2/3
BR112012003103A2 (pt) tratamento de células de astrócitos tumorais com inibidor de receptores de endotelina
ECSP11011383A (es) Sal de sodio de ácido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il]amino}benzoico como inhibidor de dhodh
BRPI1014362A2 (pt) método e composição para sincronizar o tempo de inseminação
IT1392813B1 (it) Forme cristalline di dexlansoprazolo
EA201270345A1 (ru) Модифицированный фрагмент агрина, способный восстанавливать мышечную силу, для применения в качестве лекарства
BRPI1010684A2 (pt) método para determinar o potencial cardiorregenerativo de células mamíferas
TR201101807T2 (tr) Rosuvastatin kalsiyumun farmasotik bileşimleri
BRPI0807250A2 (pt) "processo de conversão de so² em sais de interesse comercial"
UA108979C2 (uk) Застосування тетоміласту при лікуванні фіброзу або легеневої емфіземи
BRPI0917425A2 (pt) método para corrigir giro lento por meio de aquecimento e têmpera
BRPI1009765A2 (pt) "coletor e processo para flutuação de componentes insolúveis de sais brutos de potássio"
CY1117185T1 (el) Κρυσταλλικες μορφες της 3-(2,6-διχλωρο-3,5-διμεθοξυ-φαινυλ)-1-{6-[4-(4-αιθυλ-πιπεραζιν-1-υλ)-φαινυλαμινο]-πυριμιδιν-4-υλ}-1-μεθυλ-ουριας και αλατα αυτων
AR109745A2 (es) Derivado de 4-pirimidinsulfamida
FR2967059B1 (fr) Composition cosmetique et procede de recourbement des fibres keratiniques
BRPI0902727E2 (pt) sistema de deambulaÇço para deficientes visuais por meio de sensores
FR2952373B1 (fr) Controle de la fertilite humaine via dpy19l2
FR2926825B1 (fr) Saleuse de voirie a faible consommation d'energie
GB0801898D0 (en) Application of light energy to mammalian skin